The Oxford Malaria Vaccine is up to 77% effective in the early stages of testing and could be a huge breakthrough in the fight against this age-old and deadly disease.
A group of researchers from the University of Oxford they say Their research is the first of all the researches of recent years to achieve the required results. They believe their vaccine could have a significant impact on the general health of people in countries affected by malaria.
The Oxford University vaccine was tested in a pilot phase on 450 children in Burkina Faso, and the results showed acceptable efficacy over a 12-month period. A larger experiment is now being conducted on 5,000 children aged 5 months to 3 years in four African countries to confirm the findings of this study.
Adrien Hill, director of the Jenner Institute and a professor of vaccine at the University of Oxford, believes the vaccine is the first malaria vaccine to achieve the World Health Organization’s target of at least 75 percent. The most effective current malaria vaccine in the experimental phase has only achieved a 55% efficacy level.
The testing of the malaria vaccine began in 2019, before the outbreak of the corona virus, and Oxford researchers developed their own corona vaccine (in collaboration with Astrazenka) based on the vaccine information. Attempts to develop a malaria vaccine have so far been unsuccessful because there are thousands of genes for the disease and a very high level of immunity must be achieved to fight it.
Malaria is a deadly parasitic disease that is transmitted to humans through mosquito bites. Although the disease is preventable and treatable, according to the World Health Organization, in 2019, about 229 million people were infected with malaria and 409,000 people died from it. It starts with symptoms such as fever, headache, and chills, and if left untreated can quickly kill the patient. Last year, deaths from malaria in African countries were higher than deaths from the Corona virus.